JB
Jon Bruss, M.D., M.B.A.
Acting Chief Medical Officer
CrestoneCrestone Pipeline
| Drug | Indication | Phase |
|---|
| CRS3123 | Clostridioides difficile infection (CDI) | Phase 2 |
| Undisclosed Program | Antibiotic-resistant Gram-positive infections (e.g., MRSA, VRE) | Preclinical |
Leadership Team at Crestone
NJ
Nebojsa Janjic, Ph.D.
Co-Founder, CEO and President
UO
Urs Ochsner, Ph.D.
Co-Founder, COO and VP, R&D
TJ
Thale Jarvis, Ph.D.
Co-Founder, Science Advisor, former CSO
JR
John Rohloff, Ph.D.
Co-Founder, Senior Chemistry Advisor